Konar Subhas K, Maiti Tanmoy K, Bir Shyamal C, Kalakoti Piyush, Bollam Papireddy, Nanda Anil
Department of Neurosurgery, Louisiana State University Health-Shreveport, Shreveport, Louisiana, USA.
Department of Neurosurgery, Louisiana State University Health-Shreveport, Shreveport, Louisiana, USA.
World Neurosurg. 2016 Feb;86:341-8.e1-3. doi: 10.1016/j.wneu.2015.08.078. Epub 2015 Sep 6.
Primary glioblastoma multiforme of the spinal cord is a rare entity. The aim of this study was to perform an integrative analysis of patients whose cases were selected from the published studies, and to examine the influence of various factors on overall outcomes.
A PubMed search was performed for literature published from 1938 to 2015 to select the articles containing information about the demographics, tumor location, critical event (death), time to events, and treatment characteristics.
One hundred twenty-eight cases of spinal glioblastoma were selected for analysis. Patients between 18 and 65 years of age had a better overall survival rate (14 months) compared with those of "extreme" age outside that range (<18 years, 10.5 months, and >65 years, 2 months; log-rank P = 0.0005). Univariate analysis showed age between 18 and 65 years (hazard ratio [HR] = 0.121; 95% confidence interval [CI] = 0.04-0.37; P = 0.0005) and surgery with radiotherapy (HR = 3.71; 95% CI = 1.36-10.13; P = 0.01) had a significant correlation with overall survival. In multivariate analysis, thoracic spine (odds ratio [OR] = 0.154; 95% CI = 0.033-0.717; P = 0.017) and conus (OR = 0.091; 95% CI = 0.010-0.798; P =0.030) tumor had a lesser chance for mortality at 6 months. Patients who received adjuvant therapy had a better median survival than those who had surgery (log-rank P = 0.0005).
In this systemic analysis of primary spinal glioblastoma multiforme, we found that surgery followed by adjuvant therapy (radiotherapy, chemotherapy, or both) was significantly associated with improved survival. The additional finding was that overall median survival was better in the age group of 18-65 years (68 cases) compared with the extremes (<18 years, 53 cases; >65 years, 4 cases).
原发性脊髓多形性胶质母细胞瘤是一种罕见的疾病。本研究的目的是对从已发表研究中选取的患者病例进行综合分析,并研究各种因素对总体预后的影响。
在PubMed上检索1938年至2015年发表的文献,以筛选出包含人口统计学、肿瘤位置、关键事件(死亡)、事件发生时间和治疗特征等信息的文章。
选取128例脊髓胶质母细胞瘤病例进行分析。18至65岁的患者总体生存率较好(14个月),而年龄在该范围之外的“极端”年龄患者(<18岁,10.5个月;>65岁,2个月;对数秩检验P = 0.0005)则较差。单因素分析显示,18至65岁的年龄(风险比[HR]=0.121;95%置信区间[CI]=0.04 - 0.37;P = 0.0005)以及手术联合放疗(HR = 3.71;95%CI = 1.36 - 10.13;P = 0.01)与总体生存显著相关。多因素分析中,胸椎(比值比[OR]=0.154;95%CI = 0.033 - 0.717;P = 0.017)和圆锥(OR = 0.091;95%CI = 0.010 - 0.798;P = 0.030)肿瘤在6个月时死亡几率较低。接受辅助治疗的患者中位生存期比接受手术的患者更好(对数秩检验P = 0.0005)。
在本次对原发性脊髓多形性胶质母细胞瘤的系统分析中,我们发现手术联合辅助治疗(放疗、化疗或两者皆用)与生存率提高显著相关。另外还发现,18至65岁年龄组(68例)的总体中位生存期比极端年龄组(<18岁,53例;>65岁,4例)更好。